Anti-immunoglobulin e in the treatment of refractory atopic dermatitis

Southern Medical Journal

Volumn 103, Issue 6, 2010, Pages 554-558

  Amrol, David ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Atopic dermatitis; IgE; Omalizumab; Xolair

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CALCINEURIN INHIBITOR; CETIRIZINE; CLOBETASOL; CORTICOSTEROID; DOXEPIN; ETANERCEPT; FLUTICASONE; IMMUNOGLOBULIN E; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHOTREXATE; MOMETASONE FUROATE; MONTELUKAST; OMALIZUMAB; PIMECROLIMUS;

ABSENCE OF SIDE EFFECTS; ADULT; ALLERGIC RHINITIS; ANTIBIOTIC THERAPY; ARTICLE; ASTHMA; ATOPIC DERMATITIS; CASE REPORT; CHILD; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; ECZEMA; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRESCHOOL CHILD; PSORIASIS; SCHOOL CHILD;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ADULT; ANTI-ALLERGIC AGENTS; ANTIBODIES, MONOCLONAL; CHILD; DERMATITIS, ATOPIC; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN E; MALE;

EID: 77953287338     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181de0cf6     Document Type: Article

References (21)

1. Boguniewicz M. Atopic dermatitis: beyond the itch that rashes. Immunol Allergy Clin North Am 2005;25:333-351, vii.
2. Boguniewicz M, Schmid-Grendelmeier P, Leung DY. Atopic dermatitis. J Allergy Clin Immunol 2006;118:40-43.
3. Habif TP. Atopic Dermatitis, in Habif TP (ed): Clinical Dermatology: A Color Guide to Diagnosis and Therapy. St. Louis, Missouri, Mosby, Inc., 2004, ed 4, pp 107-114, 121-127.
4. Boguniewicz M, Lueng DY. Adkinson: Middleton's Allergy: Principles and Practice. St. Louis, Missouri, Mosby, Inc., 2003, ed 6.
5. Citation removed in proof.
6. Lim H. Eczema. Cecil Textbook of Medicine. Philadelphia, PA, W.B. Saunders Company. 2004, ed 22, pp 2459-2460.
7. Vigo P, Girgis KR, Pfuetze BL, et al. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 2006;55:168-170.
8. Gottlieb AB. Therapeutic options in the treatment of psoriasis and atopic dermatitis. J Am Acad Dermatol 2005;53(1 suppl 1):S3-S16.
9. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003;361:151-160. (Pubitemid 36092023)
10. Nelson RP Jr, Ballow M. 26. Immunomodulation and immunotherapy: drugs, cytokines, cytokine receptors, and antibodies. J Allergy Clin Immunol 2003;111(2 suppl):S720-S743.
11. Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005;53:338-340.
12. Lane JE, Cheyney JM, Lane TN, et al. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006;54:68-72.
13. Ruffin CG, Busch BE. Omalizumab: a recombinant humanized anti-IgE antibody for allergic asthma. Am J Health Syst Pharm 2004;61:1449-1459.
14. Dibbern DA. Urticaria: selected highlights and recent advances. Med Clin North Am. 2006;90:187-209.
15. Belloni B, Ziai M, Lim A, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007;120:1223-1225.
16. Citation removed in proof.
17. Sheinkopf LE, Rafi AW, Do LT, et al. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 2008; 29:530-537.
18. Kunz B, Oranje AP, Labrèze L. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195:10-19.
19. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1993;186:23-31.
20. Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy 2009;39:788-797.
21. Jones HE, Inouye JC, McGerity JL. Atopic disease and serum immunoglobulin- E. Br J Dermatol 1975;92:17-25.